参考文献
[1] 国家食品药品监督管理局 . 关于发布化学仿制药参比制剂遴选与确定程序的公告 [EB/OL]. (2019-03-25) [2021-10-06]. https://www. nmpa. gov.
cn/xxgk/ggtg/qtggtg/20190328162401710.html.National Medical Produces Administration (NMPA).Announcement on the selection and
determinationprocedure of reference preparations for chemical genericdrugs [EB/OL]. (2019-03-25) [2021-10-06].
https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20190328162401710.html.
[2] 刘 冬, 哈莉莉, 李 芳, 等. 仿制药质量和疗效一致性评价参比制剂申请平台情况分析及参比制剂选择的几点考虑 [J].中国临床药理学杂志, 2019, 35(23): 3158-3161.Liu D, Ha L L, Li F, et al. Analysis and consideration onthe applications of the reference preparation platform forthe chemical generic drugs [J]. Chin J Clin Pharmacol,2019, 35(23): 3158-3161.
[3] 胡 宇, 宗 欣, 于 淼, 等 . 国外仿制药一致性评价经验与启示 [J]. 中国药物评价, 2020, 37(5): 327-331.Hu Y, Zong X, Yu N, et al. Experience and enlightenmentof foreign generic drug consistency evaluation [J]. Chin JDrug Eval, 2019, 35(23): 3158-3161.
[4] 许鸣镝, 牛剑钊, 杨东升, 等. 欧盟仿制药参比制剂介绍[J]. 中国新药杂志, 2017, 26(24): 2933-2936.Xu M D, Niu J Z, Yang D S, et al. The introduction of thereference medicinal products for marketing authorizationapplication of generic medicinal products in the EU [J].Chin J New Drugs, 2017, 26(24): 2933-2936.
[5] 国务院 . 国务院关于改革药品医疗器械审评审批制度的意见 [EB/OL]. (2015-08-09)[2021-10-06]. http://www.gov.cn/zhengce/content/2015-08/18/content_10101.htm.The State Council. Opinions of the State Council onreforming the review and approval system of drugs andmedical devices [EB/OL]. (2015-08-09) [2021-10-06].http://www. gov. cn/zhengce/content/2015-08/18/content_10101.htm.
[6] 国务院办公厅 . 国务院办公厅关于开展仿制药质量和疗效一致性评价的意见 [EB/OL]. (2016-03-05) [2021-10-06]. http://www. gov.
cn/zhengce/content/2016-03/05/content_5049364.htm.General Office of the State Council. Opinions of GeneralOffice of the State Council on the consistency evaluationof quality and efficacy of generic drugs [EB/OL]. (2016-03-05) [2021-10-06]. http://www. gov. cn/zhengce/content/2016-03/05/content_5049364.htm.
[7] 国家食品药品监督管理总局 . 关于发布仿制药质量和疗效一致性评价参比制剂备案与推荐程序的公告 [EB/OL]. (2016-05-19) [2021-10-06]. https://www. nmpa.
gov.cn/xxgk/ggtg/qtggtg/20160519194501890.html.State Food and Drug Administration.
Announcement onfiling and recommending procedures for referencepreparations for consistency evaluation of quality andefficacy of generic drugs [EB/OL]. (2016-05-19) [2021-10-06]. https://www. nmpa. gov. cn/xxgk/ggtg/qtggtg/20160519194501890.html.
[8] 国家药品监督管理局药品审评中心 . 关于开通仿制药质量和疗效一致性评价专栏的通知[EB/OL]. (2017-12-08) [2021-10-06]. https://www. cde. org.
cn/yzxpj/news/viewInfoCommon/2fd4e28bb88650f95530049ef3291eef.Center for Drug Evaluation, National Medical ProducesAdministration. Notice on opening the column of qualityand efficacy consistency evaluation of generic drugs [EB/OL]. (2017-12-08) [2021-10-06]. https://www./yzxpj/news/viewInfoCommon/2fd4e28bb88650f95530049ef3291eef.
[9] 国家药品监督管理局药品审评中心. 关于公开征求«化学仿制药参比制剂遴选申请资料要求(征求意见稿)»意见 的 通 知 [EB/OL]. (2020-08-05) [2021-10-06]. https://www. cde. org.
cn/yzxpj/news/viewInfoCommon/c9bf07594d518cdfdbca3daeb4f3a189.Center for Drug
Evaluation, National Medical ProducesAdministration. Notice on soliciting comments onapplication requirements for selection of referencepreparations for chemical generic drugs (public draft) [EB/OL]. (2020-08-05) [2021-10-06]. https://www. .
cn/yzxpj/news/viewInfoCommon/c9bf07594d518cdfdbca3daeb4f3a189.
[10] 国家药品监督管理局药品审评中心. 关于发布«化学仿制药参比制剂遴选申请资料要求»的通告 [EB/OL].(2020-10-19)[2021-10-06]. https://www./yzxpj/news/viewInfoCommon/1c15428178255464bd316f8c171a038c.Center for Drug Evaluation, National Medical ProducesAdministration. Circular on the issuance of applicationrequirements for selection of reference preparations forchemical generic drugs [EB/OL]. (2020-10-19) [2021-10-06]. https://www. cde. org.
cn/yzxpj/news/viewInfoCommon/1c15428178255464bd316f8c171a038c.
[11] 国家食品药品监督管理总局 . 总局关于发布化学药品注册分类改革工作方案的公告 [EB/OL]. (2016-03-04)[2021-10-08].
http://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20160309151801706.html.State Food and Drug Administration (SFDA).Announcement on the work plan for classification reformof chemical drugs registration [EB/OL]. (2016-03-04) [2021-10-08].
http://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20160309151801706.html.
[12] 国家药品监督管理局 . 国家药监局关于发布化学药品注册分类及申报资料要求的通告[EB/OL]. (2020-06-30) [2021-10-10]. https://www. nmpa. gov.
cn/zhuanti/ypzhcglbf/ypzhcglbfzhcwj/20200630180301525.html.National Medical Produces Administration (NMPA).Circular on the issuance of registration classification andapplication requirements for chemical drugs [EB/OL].(2020-06-30) [2021-10-10]. https://www. nmpa. gov. cn/zhuanti/ypzhcglbf/ypzhcglbfzhcwj/20200630180301525.html.
[13] 刘 冬, 李 芳, 安 娜, 等 . 我国化学仿制药参比制剂遴选进展及其几点考虑 [J]. 中国临床药理学杂志, 2021,37(6): 783-787.Liu D, Li F, An N, et al. Progress and consideration ofreference selection of chemical generic drugs in China[J]. Chin J Clin Pharmacol, 2021, 37(6): 783-787.
[14] 国家药品监督管理局药品审评中心 . 国家药监局药审中心关于发布«化学药品注册受理审查指南(试行)»的通 告 [EB/OL]. (2020-07-03) [2020-10-06]. https://www.cde. org.
cn/main/news/viewInfoCommon/6386d7ca5a1515db4259acb1b8f16333.Center for Drug Evaluation, National Medical ProducesAdministration. Circular on the issuance of guidelines foraccepting and reviewing registration of chemical drugs(trial) [EB/OL]. (2020-07-03) [2021-10-06].
https://www.. cn/main/news/viewInfoCommon/6386d7ca5a1515db4259acb1b8f16333.
[15] 国家食品药品监督管理总局 . 总局关于仿制药质量与疗效一致性评价中改规格药品(口服固体制剂)评价一般考虑等 3 个技术指南的通告 [EB/OL]. (2017-02-17) [2021-10-10]. https://www. nmpa. gov. cn/directory/web/nmpa/xxgk/ggtg/qtggtg/20170217105901435.html.State Food and Drug Administration (SFDA). Notice of 3technical guidelines on general considerations forevaluation of modified drugs (oral solid preparations) inevaluation of quality and efficacy consistency of genericdrugs [EB/OL]. (2017-02-17) [2021-10-10]. https://www.nmpa. gov.
cn/directory/web/nmpa/xxgk/ggtg/qtggtg/20170217105901435.html.
[16] 国家药品监督管理局药品审评中心 . 国家药监局药审中心关于发布«化学仿制药参比制剂目录(第四十六批)»的公示 [EB/OL]. (2020-06-29)[2021-10-08]. https://www. cde. org.
cn/yzxpj/news/viewInfoCommon/d29726ca5441451a55f42ff247ccf93b.Center for Drug Evaluation, National Medical ProducesAdministration. Publication of catalogue of referencepreparations for chemical generic drugs (46th batch) [EB/OL]. (2020-06-29) [2021-10-08]. https://www. cde. org.
cn/yzxpj/news/viewInfoCommon/d29726ca5441451a55f42ff247ccf93b.
[17] 国家药品监督管理局药品审评中心 . 常见一般技术问题(序号 2) [EB/OL]. (2021-06-08) [2021-10-08].
https://www. . cn/main/xxgk/listpage/07edef25f1e7354bfd8490baa0ce056b.Center for Drug Evaluation, National Medical ProducesAdministration. Common technical questions (No 2.)[EB/OL]. (2021-06-08) [2021-10-08]. https://www. .
cn/main/xxgk/listpage/07edef25f1e7354bfd8490baa0ce056b.
[18] 赵 飞, 赵紫楠, 薛 薇, 等. 我国国家基本药物目录中仿制药参比制剂设立情况研究 [J]. 中国药事, 2021, 35(9): 1000-1006.Zhao F, Zhao Z N, Xue W, et al. On the Establishment ofGeneric Reference Formulations in China's NationalEssential Drug List [J]. Chin Pharma Aff, 2021, 35(9):1000-1006.